Clinical Trial Update: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) [Phase 3]

View source ↗

Summary

Phase 3 extension study ROMANA 3 evaluated anamorelin HCl for NSCLC-associated cachexia; results completed and posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cachexia
• Non-small Cell Lung Cancer

Drugs mentioned

• Anamorelin HCl (anamorelin hydrochloride)

Snippet

Sponsor: Helsinn Therapeutics (U.S.), Inc | Conditions: Cachexia, Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-07-11